MMS Holdings Expert Insights Blog
Experts at MMS share their insights on trending
topics in the pharmaceutical industry.
MMS Hires CRO Leader Lisa James as Director of Business Operations and Client Relations
Durham, N.C. (June 13, 2018) – MMS Holdings Inc. (MMS) – a leading global clinical research organization – announced today that Lisa James has joined as Director, Business Operations and Client Relations. James brings a depth of industry and business experience,...
Building a robust clinical data science process
During PhUSE US Connect 2018 – the clinical data science conference – in Raleigh, North Carolina, MMS data science experts presented a paper and corresponding poster, titled Big Data Paradox: Development of a Unique and Repeatable Analytical Process while Implementing...
MMS Promotes Two Leaders at its Asia Headquarters amid Strong Growth Period
Is among the lowest attrition rates in the pharmaceutical industry regionally Bangalore, India (June 7, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today two major promotions at its Asia headquarters, including Dr....
Ask the Expert: The Future of Drug Development
The size of the global pharmaceutical market will reach $1.12 trillion by the year 2022, according to Pharmaceutical Commerce. Yet, many questions linger about what the future of drug development will look like, including technology that will impact the industry and...
Why Should GDPR Matter to all Clinical Research Firms?
Since the beginning of 2018, there has been a growing interest from pharmaceutical and biotech firms in the United States regarding the basic tenets of the European Union’s (EU) new General Data Protections Regulation (GDPR) law. With more than 50 percent of all...
Start plain language summaries early or get left behind
In July 2019, the European Union (EU) Clinical Trial Regulation No. 536/2014 will go into effect, requiring all sponsors, including academia, conducting clinical trials to draft lay or plain language summaries for phase 2-4 clinical trials. These lay summaries need to...
Perfecting the hand-off from programming and statistics to regulatory operations
A room full of statisticians and clinical programmers were floored to hear that regulatory operations experts were working with nearly 500,000 pages of text in a recent New Drug Application (NDA). This is how Mary Anne Potok, Technical Manager, Regulatory Operations,...
The Benefits and Risks of Expedited Drug Development and Review Pathways
The Food and Drug Administration’s (FDA) drug approval process puts patient health at the forefront and subjects each new drug candidate to several stages of testing in both preclinical and clinical settings. This rigorous process typically requires 10 years or more...
MMS Partners with University of Findlay to Provide Medical Writing and Clinical Trial Disclosure Courses
Canton, Mich. and Findlay, Ohio (May 1, 2018) – MMS Holdings Inc. (MMS) – a global, leading clinical research organization – announced today that they have partnered with the University of Findlay to provide online medical writing and clinical trial disclosures...